Literature DB >> 24816938

Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithm.

Ruediger P Laubender1, Julia Lynghjem, Melvin D'Anastasi, Volker Heinemann, Dominik P Modest, Ulrich R Mansmann, Ute Sartorius, Michael Schlichting, Anno Graser.   

Abstract

OBJECTIVES: To evaluate the agreement between tumour volume derived from semiautomated volumetry (SaV) and tumor volume defined by spherical volume using longest lesion diameter (LD) according to Response Evaluation Criteria In Solid Tumors (RECIST) or ellipsoid volume using LD and longest orthogonal diameter (LOD) according to World Health Organization (WHO) criteria.
MATERIALS AND METHODS: Twenty patients with metastatic colorectal cancer from the CIOX trial were included. A total of 151 target lesions were defined by baseline computed tomography and followed until disease progression. All assessments were performed by a single reader. A variance component model was used to compare the three volume versions.
RESULTS: There was a significant difference between the SaV and RECIST-based tumour volumes. The same model showed no significant difference between the SaV and WHO-based volumes. Scatter plots showed that the RECIST-based volumes overestimate lesion volume. The agreement between the SaV and WHO-based relative changes in tumour volume, evaluated by intraclass correlation, showed nearly perfect agreement.
CONCLUSIONS: Estimating the volume of metastatic lesions using both the LD and LOD (WHO) is more accurate than those based on LD only (RECIST), which overestimates lesion volume. The good agreement between the SaV and WHO-based relative changes in tumour volume enables a reasonable approximation of three-dimensional tumour burden. KEY POINTS: • Tumour response in patients undergoing chemotherapy is assessed using CT images • Measurements are based on RECIST (unidimensional)-based or WHO (bidimensional)-based criteria • We calculated tumour volume from bidimensional target lesion measurements • This formula provides good tumour volume approximation, based on semiautomated volumetry.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24816938     DOI: 10.1007/s00330-014-3195-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  17 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.

Authors:  Binsheng Zhao; Geoffrey R Oxnard; Chaya S Moskowitz; Mark G Kris; William Pao; Pingzhen Guo; Valerie M Rusch; Marc Ladanyi; Naiyer A Rizvi; Lawrence H Schwartz
Journal:  Clin Cancer Res       Date:  2010-06-09       Impact factor: 12.531

3.  Semi-automated volumetric analysis of lymph node metastases during follow-up--initial results.

Authors:  Michael Fabel; H Bolte; H von Tengg-Kobligk; L Bornemann; V Dicken; S Delorme; H-U Kauczor; M Heller; J Biederer
Journal:  Eur Radiol       Date:  2010-10-17       Impact factor: 5.315

4.  Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.

Authors:  Hubert Piessevaux; Marc Buyse; Michael Schlichting; Eric Van Cutsem; Carsten Bokemeyer; Steffen Heeger; Sabine Tejpar
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  Tumor volume measurement errors of RECIST studied with ellipsoids.

Authors:  Zachary H Levine; Benjamin R Galloway; Adele P Peskin; Claus P Heussel; Joseph J Chen
Journal:  Med Phys       Date:  2011-05       Impact factor: 4.071

7.  Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

Authors:  Nicolas Moosmann; Ludwig Fischer von Weikersthal; Ursula Vehling-Kaiser; Martina Stauch; Holger G Hass; Herrmann Dietzfelbinger; Daniel Oruzio; Stefan Klein; Klaus Zellmann; Thomas Decker; Mathias Schulze; Wolfgang Abenhardt; Gerhard Puchtler; Herbert Kappauf; Johann Mittermüller; Christopher Haberl; Andreas Schalhorn; Andreas Jung; Sebastian Stintzing; Volker Heinemann
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

8.  Semi-automated volumetric analysis of lymph node metastases in patients with malignant melanoma stage III/IV--a feasibility study.

Authors:  M Fabel; H von Tengg-Kobligk; F L Giesel; L Bornemann; V Dicken; A Kopp-Schneider; C Moser; S Delorme; H-U Kauczor
Journal:  Eur Radiol       Date:  2008-02-15       Impact factor: 5.315

9.  Liver resection for multiple colorectal metastases: influence of parenchymal involvement and total tumor volume, vs number or location, on long-term survival.

Authors:  Giorgio Ercolani; Gian Luca Grazi; Matteo Ravaioli; Matteo Cescon; Andrea Gardini; Giovanni Varotti; Massimo Del Gaudio; Bruno Nardo; Antonino Cavallari
Journal:  Arch Surg       Date:  2002-10

10.  Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial).

Authors:  H Piessevaux; M Buyse; W De Roock; H Prenen; M Schlichting; E Van Cutsem; S Tejpar
Journal:  Ann Oncol       Date:  2009-05-22       Impact factor: 32.976

View more
  3 in total

1.  Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver.

Authors:  Julius Chapiro; Rafael Duran; MingDe Lin; Rüdiger Schernthaner; David Lesage; Zhijun Wang; Lynn Jeanette Savic; Jean-François Geschwind
Journal:  Eur Radiol       Date:  2015-01-31       Impact factor: 5.315

2.  Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients.

Authors:  Sree Harsha Tirumani; Atul B Shinagare; Ailbhe C O'Neill; Mizuki Nishino; Michael H Rosenthal; Nikhil H Ramaiya
Journal:  Eur Radiol       Date:  2015-05-20       Impact factor: 5.315

3.  Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1/IKZF1.

Authors:  Erin L Symonds; Susanne K Pedersen; Bernita Yeo; Hiba Al Naji; Susan E Byrne; Amitesh Roy; Graeme P Young
Journal:  Mol Oncol       Date:  2022-01-24       Impact factor: 7.449

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.